Zynlonta’s confirmation looks in doubt
Lotis-5 hits on PFS, but misses on OS, and deaths raise concerns.
Lotis-5 hits on PFS, but misses on OS, and deaths raise concerns.
ADC Therapeutics’ Lotis-5 confirmatory trial of its CD19-targeting ADC Zynlonta in second-line DLBCL looked in trouble two years ago, and now the study has produced mixed topline results that sent the…
This content is only accessible for subscribers -
.
Interested in becoming a subscriber?
Click here.
0
